EpiCor ® and EpiCor ® Junior
EpiCor ® 30 capsules
EpiCor ® Junior 60 capsules
A Revolutionary Dietary Ingredient for Immune Health!
The Possible Benefits of EpiCor®Junior, a Dietary Supplement
• An all-natural, high-metabolite immunogen that nourishes the body's immune system
A Top Ten Natural Immune Enhancer• EpicorTM improves CD4/CD8 T-cell ratio: CD4 (helpher) cells facilitie and coordinate immune response, while CD8 (suppressor) cells, in part, down-regulate this response.
• EpicorTM significally inhibits the growth of E. coli and Candida tropicalis, even at concentrations as low as 1 part per trillion. Not only does EpicorTM inhibit the growth of undesirable, pathogenic bacteria & fungus, but given the proper growth environment, this could encourage the growth of favourable bacterial organisms in the gut whose secondary metabolites contribute to human health.” ~ Extracted from Infection Protection: Pandemic by World Health Net
They all impact your immune system.
Balance your immune system with EpiCor®.
Strengthen all three lines of your natural defenses with EpiCor® & EpiCor Junior®:
• The Physical Barrier (skin, mucous membranes)
• Search and Destroy (macrophages, granulocytes, natural killer (NK) cells)
• Antibody Manufacture (T-lymphocytes [T-cells], B-lymphocytes [B-cells])
EpiCor® is a potent immune system modulator that helps regulate your body's natural immune defenses. EpiCor® primes the immune responder cells in the blood so that they are on high alert to attack viruses and bacteria. At the same time, EpiCor® redirects the immune system helping to prevent the immune cells from attacking the body itself. In other words, EpiCor® primes the immune system to attack non-self proteins, like bacteria and viruses, while supporting the immune system's ability to recognize and to leave 'self' proteins alone. The immune system's attack of 'self' proteins is the main feature of inflammation and inflammatory reactions.
EpiCor® enhances the body's immune reaction by increasing the levels of CD4 "helper cells" and at the same time decreasing levels of CD8 "suppressor" cells. EpiCor® supports hyperactive immune systems to give them a more balanced, normal immune response.
EpiCor® should be taken daily to help minimize the risk and severity of colds and flus by improving the CD4/CD8 helper/suppressor cell ratio, resulting in a powerful shift in the body's ability to defend itself against infectious agents. There is evidence that EpiCor®'s immune system modulatory effects improves over time.
Another important mechanism of action of EpiCor® is that it increases the levels of secretory IgA one of the five immunoglobulins that is a major first line of defense in infections that enter via mucosal surfaces. Secretory IgA envelops and makes our mucous membranes impervious to pathogens including bacteria and viruses. Secretory IgA has been proven a powerful antiviral agent. It not only protects the mouth and nasal passages, but also protects the mucous that lines the entire gastrointestinal tract.
EpiCor® is a yeast-based product manufactured by a multi-stage fermentation process. It has not been shown to have any negative effect on persons suffering from Candida albicans, or candidiasis. On the contrary, EpiCor® has been effective against E. Coli and Candida tropicalis. It acts as a probiotic, supporting healthy gastrointestinal flora. The proprietary MetaGen-4™ fermentation process also produces powerful antioxidants, including catechins, polyphenols, and resveratrol, all of which all contribute to EpiCor®’s high free radical quenching abilities. It has a high ORAC rating and quenches free radicals at levels as low as 1 part per trillion.
Scientists have conducted a number of human studies on EpiCor® in recent years, and EpiCor® has emerged as a powerful immune-modulating natural agent.
Human Clinical Trials
The gold standard for research in the dietary supplement industry is the human clinical trial. The human studies conducted using EpiCor® showed a strong trend toward its ability to support a balanced immune system with dosage amounts of only 500 mg daily over several weeks. The studies focused on the immune system’s ability to help lessen the duration and symptoms of a cold or flu, as well as reduce the problems associated with seasonal allergies. Furthermore, a recent animal study demonstrates the antioxidant properties of EpiCor®.
Study #1: Strengthening the Body’s Immunological Envelope
The first human clinical trial aimed to prove that EpiCor® would provide the same effects in humans as it does in animals, but with smaller doses. The study comprised of 22 people who had neither been exposed to nor taken EpiCor® before. The participants were given doses of 500 mg per day over a period of 30 days. Saliva samples were taken twice a day, 3 times a week for a month, and saliva secretory IgA was measured to establish the baseline concentration. IgA, or Immunoglobulin A, is an antibody and, in its secretory form (sIgA), is the main antibody found in mucous secretions including tears, saliva, and other bodily secretions. Because it is resistant to degradation by enzymes, it can survive harsh environments such as the digestive and respiratory tracts, to provide protection against microbes that multiply in body secretions, acting as a protective immunological envelope around mucous membranes.
The subjects of this study were given 500 mg of EpiCor® per day for 60 more days, and the sIgA monitoring was continued. After 30 days, there was a strong trend for increased sIgA over baseline, and after 60 days the average sIgA levels among the subjects were significantly higher than the baseline levels. This indicates that EpiCor® increased this important immune defence component in just a matter of a few weeks.
Study #2: Seasonal Allergy and Immune Support
Another human clinical trial investigated the effects of EpiCor® on several markers of immune function. In this double-blind, placebo-controlled trial, subjects were given either EpiCor® (1,000 mg) or placebo for 5 weeks. At the end of 5 weeks, the salivary sIgA increased while the serum IgE decreased. These results helped confirm the findings of the previous trial supporting the efficacy of EpiCor®. On the other hand, the decreased serum IgE suggests the important immune balancing effects of EpiCor®.
Since this trial was conducted in spring when allergies are a problem for many people, one would expect serum IgE to increase, as this immune parameter is associated with allergies. This was seen in the controls. However, in the EpiCor® group, the levels stayed nearly at baseline, giving laboratory confirmation of the subjects’ reporting fewer allergy problems than usual. This was also reflected in a standardized questionnaire showing fewer health complaints with the EpiCor® group. It was also observed that cytokine profiles were shifting in the EpiCor® group—from Th1 (pro-inflammatory) to Th2 (pro-adaptive) and vice versa—again demonstrating the immune balancing properties of EpiCor®.
Study #3: Upper Respiratory Tract Health
A third study assessed the clinical benefits of EpiCor® in a large, independently conducted double-blind, placebo-controlled human clinical trial. To do this, 230 people were recruited to take either EpiCor® or placebo, to study the effects on upper respiratory tract infections (URTI). This large group was chosen to represent the general population aged 18 years and older. The trial took place during the worst cold and flu months - January, February and March - in South Dakota. Subjects received physical examinations at screening to ensure a healthy study population, and were randomly assigned to receive either EpiCor® or placebo. Fasting blood samples were taken at randomization, week 6 and at week 12 (when the trial ended). Each subject was given a diary and instructed to record duration and severity of cold and flu symptoms.
In the subjects taking EpiCor®, the incidence of URTIs was statistically and significantly reduced. A statistic known as the “p-value” was 0.0000008 - meaning that the probability that the reduction in URTIs in the EpiCor® group occurred by chance was less than one in a million. Additionally, in the rare cases when the EpiCor® subjects did get URTIs, the duration of the symptoms was significantly shorter.
Conclusion
These human clinical trials support the body of past research that establishes EpiCor® as a means to support immune health. In these studies, EpiCor® showed a strong trend toward supporting a balanced immune system with smaller dosage amounts than that given to animals. These results demonstrate that EpiCor® may have a strong role to play in optimizing immune health.
Kids are more vulnerable to a number of pathogens, due to their underdeveloped immune systems and their frequent exposure to a large number of other children. Not only is it heartbreaking to watch the littlest members of our families become sick, it also means that inevitably, one or more parent will miss work because of a child’s illness, indicating that childhood illness results in a cost to our economy.
Day care centers and schools are breeding grounds for a variety of harmful microorganisms. Children attending day-care centers are at an increased risk for becoming colonized by Haemophilus influenzae, a common cause of otitis media. Furthermore, children in day care were reported to have more symptoms than children in home care such as wheezing, coughing at night apart from colds that lasted 12 months, doctor-diagnosed asthma, doctor-diagnosed hay fever, eczema, allergic reactions to foods, greater than 6 colds in a year, and ear infections.
When children experience infections, it can lead to life-long consequences. Helicobacter Pylori infection is very common in young children, who acquire the organism that later leads to a chronic infection, causing a lifelong susceptibility to peptic ulcers. Another example is the link between day-care attendance during the first six months of life, "physician-diagnosed infections" between 5 and 10 years of age, and an increased risk for Crohn's disease.
Antibiotics, while they can save lives and are sometimes necessary, are not always the solution. In fact, children colonized with H. influenzae were more likely to carry resistant strains of the bacterium if they were taking an antibiotic.
Clearly, children are in need of a convenient, dependable way to boost their immune systems. EpiCor™ Junior, a new supplement shown to improve the ratio of CD4 to CD8 immune cells and to increase the killing efficiency of natural killer cells, helps kids boost their immune systems. As children go back to school and the flu season approaches, EpiCor Junior’s ability to enhance levels of secretory IgA provides kids with an immunological envelope around their mucous membranes where viruses and bacteria enter the body, an effect that further supports immune health.
Epicor®
Serving Size: 1 capsule
Amount per serving
Dried yeast fermentate (Epicor®) 500mg
Other ingredient: Gelatin
Directons: Take 1 capsule daily.
Epicor® Junior
Serving Size: 1 capsule
Amount per serving
Dried yeast fermentate (Epicor®) 150mg
Other ingredient: Gelatin
Directons: Take 1 to 2 capsules daily.
*As per US federal guidelines, we need to inform you that these statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
0 comments:
Post a Comment